Modafinil for the Treatment of Alcohol Use Disorders
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/17/2018 |
| Start Date: | December 11, 2017 |
| End Date: | December 31, 2019 |
| Contact: | Claire Wilcox, MD |
| Email: | cwilcox@mrn.org |
| Phone: | 505-633-8102 |
Modafinil for the Treatment of Alcohol Use Disorders: Targeting Impaired Response Inhibition
Alcohol use disorder (AUD) is a major cause of morbidity and mortality and more treatments
are needed, especially pharmacotherapies. There are a variety of efficacious treatments for
AUD, but effect sizes are small, and vary from study to study. Medications may be more
effective if particular subgroups of AUD are targeted. Identifying the mechanisms of action
of a particular medication will help identify the subtypes more likely to respond to therapy.
Global impulse control is a rational treatment target, and improving it is a likely
mechanisms by which some medications for AUD work, especially in subtypes of AUD with
impaired impulse control at baseline. Modafinil is a medication that is FDA approved for the
treatment of narcolepsy, and is relatively safe and tolerable. There is reason to believe it
may improve impulse control, and underlying neural circuitry, and may work best to improve
alcohol use outcomes in AUD with poor impulse control. The overall aim of this study is to
investigate the effects of modafinil on task performance and the integrity of neural circuits
mediating response inhibition in treatment-seeking AUD with poor response inhibition, to
establish target engagement. Secondary aims are to measure whether target engagement mediates
improvement in alcohol use outcomes, and to utilize machine learning to identify neural and
behavioral markers which best predict treatment outcomes. Twenty-four individuals with AUD
and impaired response inhibition will be enrolled in the study, randomized to modafinil or
placebo, and treated for 6 weeks. Functional magnetic resonance imaging brain scans during a
response inhibition task and during rest will be obtained at baseline and 2 weeks. Aversive
stimuli will be included in the response inhibition task to assure that efficacy generalizes
to several conditions. Diffusion imaging and arterial spin labeling sequences will also be
obtained. Investigators predict that modafinil will significantly increase brain activity in
the medial and lateral prefrontal cortex during response inhibition, thereby establishing
target engagement, and that it will improve alcohol use outcomes. Findings will provide
information about whether or not a larger R01 trial investigating the efficacy of modafinil
for individuals with AUD and impaired response inhibition is warranted.
are needed, especially pharmacotherapies. There are a variety of efficacious treatments for
AUD, but effect sizes are small, and vary from study to study. Medications may be more
effective if particular subgroups of AUD are targeted. Identifying the mechanisms of action
of a particular medication will help identify the subtypes more likely to respond to therapy.
Global impulse control is a rational treatment target, and improving it is a likely
mechanisms by which some medications for AUD work, especially in subtypes of AUD with
impaired impulse control at baseline. Modafinil is a medication that is FDA approved for the
treatment of narcolepsy, and is relatively safe and tolerable. There is reason to believe it
may improve impulse control, and underlying neural circuitry, and may work best to improve
alcohol use outcomes in AUD with poor impulse control. The overall aim of this study is to
investigate the effects of modafinil on task performance and the integrity of neural circuits
mediating response inhibition in treatment-seeking AUD with poor response inhibition, to
establish target engagement. Secondary aims are to measure whether target engagement mediates
improvement in alcohol use outcomes, and to utilize machine learning to identify neural and
behavioral markers which best predict treatment outcomes. Twenty-four individuals with AUD
and impaired response inhibition will be enrolled in the study, randomized to modafinil or
placebo, and treated for 6 weeks. Functional magnetic resonance imaging brain scans during a
response inhibition task and during rest will be obtained at baseline and 2 weeks. Aversive
stimuli will be included in the response inhibition task to assure that efficacy generalizes
to several conditions. Diffusion imaging and arterial spin labeling sequences will also be
obtained. Investigators predict that modafinil will significantly increase brain activity in
the medial and lateral prefrontal cortex during response inhibition, thereby establishing
target engagement, and that it will improve alcohol use outcomes. Findings will provide
information about whether or not a larger R01 trial investigating the efficacy of modafinil
for individuals with AUD and impaired response inhibition is warranted.
see above.
Inclusion Criteria:
- Males and females age 18-65 meeting Diagnostic and Statistical Manual V criteria for
moderate or severe AUD in the past year
- Interested in cutting down or quitting
- Able to provide voluntary informed consent
- Have at least 4 heavy drinking days (≥ 5 drinks per day for men, and 4 for women) in
the past 60 days
- Stop signal reaction time on a stop signal task>233
Exclusion Criteria:
- Severe neurological conditions (severe traumatic brain injury/stroke/active seizure
disorder)
- Heart disease [mitral valve prolapse, left ventricular hypertrophy, cardiac
arrhythmias, angina, myocardial infarction, unstable angina, cardiac syncope or
pre-syncope, any electrocardiogram (ECG) finding that suggests the presence of one of
these conditions]
- Uncontrolled hypertension (systolic blood pressure >160, diastolic blood pressure
>100)
- Heart rate greater than 70% of the maximum expected for age [0.70(220-age)]
- Chronic renal or hepatic failure
- Recent pancreatitis
- Insulin-dependent diabetes
- Other urgent medical problems
- Elevated liver function tests (AST or ALT greater than 4 times normal; modafinil is
metabolized primarily by the liver)
- Schizophrenia, schizoaffective disorder, Bipolar I disorder, suicidal thoughts in the
last month
- Current moderate or severe other substance use disorder (SUD) (except nicotine or
marijuana)
- Active legal problems with the potential to result in incarceration
- Pregnancy or lactation, or child bearing age and not on birth control
- Current daily use of anti-craving medications, stimulants, benzodiazepines, opiates,
anti-psychotics; current daily use of tricyclic antidepressants, bupropion, monoamine
oxidase inhibitors, serotonin and norepinephrine reuptake inhibitors, or therapeutic
doses (for bipolar disorder) of mood stabilizers
- Taking a medication contraindicated for use with modafinil
We found this trial at
1
site
Click here to add this to my saved trials
